Willem Stemmer
About Willem Stemmer
Willem Stemmer is the Chief Executive Officer and Founder of Amunix, where he has worked since 2006. He has extensive experience in the development of novel protein pharmaceuticals and has held various leadership roles in biotechnology companies.
Work at Amunix
Willem Stemmer has served as the Chief Executive Officer and Founder of Amunix since 2006. Under his leadership, the company focuses on the design and development of novel protein pharmaceuticals. Amunix operates from Mountain View, California, and has been involved in innovative business concepts within the biotechnology sector. Stemmer's role encompasses strategic decision-making and overseeing research initiatives aimed at advancing protein-based therapeutics.
Education and Expertise
Willem Stemmer holds a Doctor of Philosophy degree in Biology from the University of Wisconsin - Madison, where he studied from 1980 to 1985. He also studied Biology at the University of Amsterdam from 1975 to 1980. Additionally, he attended Institut Montana, Zugerberg in Switzerland. Stemmer has expertise in the design of non-biological complex systems using directed evolution, which is integral to his work in protein pharmaceuticals.
Background
Before founding Amunix, Willem Stemmer held significant positions in various biotechnology companies. He was the Founder and Vice-President of Research at Maxygen from 1997 to 2003. Prior to that, he worked as a Distinguished Scientist at Affymax from 1992 to 1997. He also founded Avidia and served as Chief Scientific Officer from 2003 to 2005. His diverse background in research and development has contributed to his current role in the biotechnology industry.
Achievements in Biotechnology
In January 2010, Willem Stemmer founded Diartis Inc. to focus on the clinical development of Exenatide-XTEN, a once-a-month treatment for type II diabetes. This initiative reflects his commitment to advancing therapeutic options in the field of diabetes care. His involvement in the design and development of protein pharmaceuticals has positioned him as a notable figure in biotechnology.